Literature DB >> 19189974

GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein.

Elspeth Beauchamp1, Gulay Bulut, Ogan Abaan, Kevin Chen, Akil Merchant, William Matsui, Yoshimi Endo, Jeffrey S Rubin, Jeffrey Toretsky, Aykut Uren.   

Abstract

Ewing sarcoma family of tumors (ESFT) is an undifferentiated neoplasm of the bone and soft tissue. ESFT is characterized by a specific chromosomal translocation occurring between chromosome 22 and (in most cases) chromosome 11, which generates an aberrant transcription factor, EWS-FLI1. The function of EWS-FLI1 is essential for the maintenance of ESFT cell survival and tumorigenesis. The Hedgehog pathway is activated in several cancers. Oncogenic potential of the Hedgehog pathway is mediated by increasing the activity of the GLI family of transcription factors. Recent evidence suggests that EWS-FLI1 increases expression of GLI1 by an unknown mechanism. Our data from chromatin immunoprecipitation and promoter reporter studies indicated GLI1 as a direct transcriptional target of EWS-FLI1. Expression of EWS-FLI1 in non-ESFT cells increased GLI1 expression and GLI-dependent transcription. We also detected high levels of GLI1 protein in ESFT cell lines. Pharmacological inhibition of GLI1 protein function decreased proliferation and soft agar colony formation of ESFT cells. Our results establish GLI1 as a direct transcriptional target of EWS-FLI1 and suggest a potential role for GLI1 in ESFT tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189974      PMCID: PMC2666556          DOI: 10.1074/jbc.M806233200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

Review 1.  Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors.

Authors:  A A Sandberg; J A Bridge
Journal:  Cancer Genet Cytogenet       Date:  2000-11

2.  Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.

Authors:  Zhenyu Ji; Fang C Mei; Jingwu Xie; Xiaodong Cheng
Journal:  J Biol Chem       Date:  2007-03-12       Impact factor: 5.157

3.  Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy.

Authors:  Karl-Ludwig Schaefer; Martin Eisenacher; Yvonne Braun; Kristin Brachwitz; Daniel H Wai; Uta Dirksen; Claudia Lanvers-Kaminsky; Heribert Juergens; David Herrero; Sabine Stegmaier; Ewa Koscielniak; Angelika Eggert; Michaela Nathrath; Georg Gosheger; Dominik T Schneider; Carsten Bury; Raihanatou Diallo-Danebrock; Laura Ottaviano; Helmut E Gabbert; Christopher Poremba
Journal:  Eur J Cancer       Date:  2008-02-21       Impact factor: 9.162

4.  Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists.

Authors:  Matthias Lauth; Asa Bergström; Takashi Shimokawa; Rune Toftgård
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-09       Impact factor: 11.205

5.  Mesenchymal stem cell features of Ewing tumors.

Authors:  Franck Tirode; Karine Laud-Duval; Alexandre Prieur; Bruno Delorme; Pierre Charbord; Olivier Delattre
Journal:  Cancer Cell       Date:  2007-05       Impact factor: 31.743

6.  Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.

Authors:  Barbara Stecca; Christophe Mas; Virginie Clement; Marie Zbinden; Rafael Correa; Vincent Piguet; Friedrich Beermann; Ariel Ruiz I Altaba
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-28       Impact factor: 11.205

7.  Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo.

Authors:  Sylviane Dennler; Jocelyne André; Ismini Alexaki; Allen Li; Thierry Magnaldo; Peter ten Dijke; Xiao-Jing Wang; Franck Verrecchia; Alain Mauviel
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

8.  The EWS/FLI1 oncogenic transcription factor deregulates GLI1.

Authors:  J P Zwerner; J Joo; K L Warner; L Christensen; S Hu-Lieskovan; T J Triche; W A May
Journal:  Oncogene       Date:  2007-12-17       Impact factor: 9.867

9.  Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.

Authors:  J Taipale; J K Chen; M K Cooper; B Wang; R K Mann; L Milenkovic; M P Scott; P A Beachy
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

10.  Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.

Authors:  Kimberly Stegmaier; Jenny S Wong; Kenneth N Ross; Kwan T Chow; David Peck; Renee D Wright; Stephen L Lessnick; Andrew L Kung; Todd R Golub
Journal:  PLoS Med       Date:  2007-04       Impact factor: 11.069

View more
  85 in total

Review 1.  Targeting Hedgehog--a cancer stem cell pathway.

Authors:  Akil A Merchant; William Matsui
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

Review 2.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

3.  Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Authors:  Dave N T Aryee; Stephan Niedan; Maximilian Kauer; Raphaela Schwentner; Idriss M Bennani-Baiti; Jozef Ban; Karin Muehlbacher; Michael Kreppel; Robert L Walker; Paul Meltzer; Christopher Poremba; Reinhard Kofler; Heinrich Kovar
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

Review 4.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

5.  Arsenic: a potentially useful poison for Hedgehog-driven cancers.

Authors:  G Praveen Raju
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

6.  Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.

Authors:  Elspeth M Beauchamp; Lymor Ringer; Gülay Bulut; Kamal P Sajwan; Michael D Hall; Yi-Chien Lee; Daniel Peaceman; Metin Ozdemirli; Olga Rodriguez; Tobey J Macdonald; Chris Albanese; Jeffrey A Toretsky; Aykut Uren
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

7.  Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

Authors:  Malcolm A Smith; Min H Kang; C Patrick Reynolds; Raushan T Kurmasheva; Denise Alexander; Catherine A Billups; Jeffrey A Toretsky; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2012-02-07       Impact factor: 3.167

8.  EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Authors:  Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter
Journal:  Mol Cancer Res       Date:  2017-07-18       Impact factor: 5.852

9.  A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Authors:  Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

Review 10.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.